Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

British journal of clinical pharmacology - 1 Oct 1991

Broly F, Vandamme N, Libersa C, Lhermitte M

Abstract excerpt

1. The relationship between the metabolism of the antiarrhythmic drug mexiletine and the debrisoquine/sparteine-type polymorphism was studied in vitro, using microsomes from six human livers, and in vivo, in nine healthy drug-free volunteers with wide variation in their ability to hydroxylate debrisoquine. 2. There was a strong and similar correlation between the formation rate of both major mexiletine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Debrisoquin
Share to Hydroxylation
Share to Phenotype

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Polymorphism, Genetic

Share to Smoking

Share to Sparteine

Source

Open in PubMed Open full text

Identifiers

PMID: 1958440
DOI: 10.1111/j.1365-2125.1991.tb03931.x
PMCID: PMC1368606

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.PMID 1958440Read ↗

Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.Semantic proximity Read ↗

Influence of debrisoquine hydroxylation phenotype on the pharmacokinetics of mexiletine.Semantic proximity Read ↗

Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.Semantic proximity Read ↗

The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.Semantic proximity Read ↗

Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.Semantic proximity Read ↗

Debrisoquine phenotype and the pharmacokinetics and beta-2 receptor pharmacodynamics of metoprolol and its enantiomers.Semantic proximity Read ↗

Pharmacogenetics of Debrisoquine and its Use as a Marker For CYP2D6 Hydroxylation CapacitySemantic proximity Read ↗

Comparative effects of the diastereoisomers, quinine and quinidine in producing phenocopy debrisoquine poor metabolisers (PMs) in healthy volunteers.Semantic proximity Read ↗

Genetically determined adverse drug reactions involving metabolism.Semantic proximity Read ↗

Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.Semantic proximity Read ↗

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.Semantic proximity Read ↗

Enantioselectivity of debrisoquine 4-hydroxylation in Brazilian Caucasian hypertensive patients phenotyped as extensive metabolizers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.